---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-027966"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:23:04.388206+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics Q3 net loss widens to $32.0M; cash runway to end of 2024

## Summary
- Net loss $32.0M ($0.65/diluted share) vs $24.7M ($0.51) in Q3 2021; revenue $6.8M vs $8.5M.
- Cash, equivalents & marketable securities $366.0M at Sep 30, down from $451.5M at Dec 31, 2021; runway to end of 2024.
- Phase 1/2 trials for CFT7455 (IKZF1/3 degrader in MM/NHL) and CFT8634 (BRD9 in synovial sarcoma) advancing dose escalation.
- IND clearance for CFT1946 (BRAF-V600 degrader) in Sep; Phase 1/2 to initiate by year-end 2022.
- Upcoming milestones: CFT8919 (EGFR L858R) IND-enabling activities to complete by year-end 2022.

## SEC filing metadata
- accession: 0001628280-22-027966
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828022027966/0001628280-22-027966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828022027966/cccc-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-027966
- JSON: https://secwatch.observer/filing/0001628280-22-027966.json
- Plain text: https://secwatch.observer/filing/0001628280-22-027966.txt

## Key facts
- Earnings Releases
  C4 Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $6.8 million, net income $32.0 million, EPS $0.65.
  - Period: third quarter ended September 30, 2022
  - Revenue: $6.8 million
  - Net income: $32.0 million
  - EPS: $0.65
  - Result: reported results
  source text: will participate in a fireside chat at the Evercore ISI HealthCONx Conference. THIRD QUARTER 2022 FINANCIAL RESULTS Revenue: Total revenue for the third quarter of 2022 was $6.8 million, compared to $8.5 million for the third quarter of 2021. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828022027966/0001628280-22-027966-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.